肝细胞癌靶向治疗联合免疫治疗的研究剖析  

Analysis of targeted therapy combined with immunotherapy for hepatocellular carcinoma

作　　者：刘千琳 李秋[1] LIU Qianlin;LI Qiu(Department of Medical Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]四川大学华西医院肿瘤中心,成都610041

出　　处：《中国普外基础与临床杂志》2023年第4期392-396,共5页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：本研究通过概述肝细胞癌靶向治疗联合免疫治疗(简称“靶免联合治疗”)的最新热点研究,并对其研究设计和结果做简要剖析,旨在为临床决策及未来研究方向提供参考。总结并分析近年来肝细胞癌靶免联合治疗的相关研究方案设计及结果发现,其临床研究结果喜忧参半,这与研究设计、药物选择、患者选择、方案实施等因素密切相关。提示在解读肝细胞癌靶免联合治疗研究结果时,需要考虑疾病研究背景等多方面的因素,以期获得更全面而客观的理解。We briefly analyzed the research design and results through summarizing the latest hot spots relevant to targeted therapy in combination with immunotherapy(Abbreviated as“combination therapy”)for hepatocellular carcinoma(HCC),aiming to provide references for clinical decision-making and future research directions.It was found that the clinical study results related to combination therapy for HCC were different by summarizing the study design and results of combination therapy for HCC in recent years,which might be closely related to the study design,drug selection,research objects selection,protocol implementation,and other factors.It is suggested that a variety of factors such as disease background should be considered when combination therapy for HCC is conducted in order to obtain a more comprehensive and objective understanding.

关 键 词：肝细胞癌 系统治疗 免疫治疗 靶向治疗 

分 类 号：R735.7[医药卫生—肿瘤]